High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
- PMID: 21209378
- PMCID: PMC3952811
- DOI: 10.1182/blood-2010-09-305128
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
Abstract
Cutaneous T-cell lymphomas (CTCLs) are malignancies of skin-homing lymphoid cells, which have so far not been investigated thoroughly for common oncogenic mutations. We screened 90 biopsy specimens from CTCL patients (41 mycosis fungoides, 36 Sézary syndrome, and 13 non-mycosis fungoides/Sézary syndrome CTCL) for somatic mutations using OncoMap technology. We detected oncogenic mutations for the RAS pathway in 4 of 90 samples. One mycosis fungoides and one pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL harbored a NRAS(Q61K) amino acid change. All mutations were found in stage IV patients (4 of 42) who showed significantly decreased overall survival compared with stage IV patients without mutations (P = .04). In addition, we detected a NRAS(Q61K) mutation in the CTCL cell line Hut78. Knockdown of NRAS by siRNA induced apoptosis in mutant Hut78 cells but not in CTCL cell lines lacking RAS mutations. The NRAS(Q61K) mutation sensitized Hut78 cells toward growth inhibition by the MEK inhibitors U0126, AZD6244, and PD0325901. Furthermore, we found that MEK inhibitors exclusively induce apoptosis in Hut78 cells. Taken together, we conclude that RAS mutations are rare events at a late stage of CTCL, and our preclinical results suggest that such late-stage patients profit from MEK inhibitors.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3952811/bin/2433f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3952811/bin/2433f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3952811/bin/2433f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3952811/bin/2433f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3952811/bin/2433f5.gif)
Similar articles
-
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Cell Rep. 2014 Sep 11;8(5):1475-83. doi: 10.1016/j.celrep.2014.07.033. Epub 2014 Sep 4. Cell Rep. 2014. PMID: 25199829
-
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.Oncotarget. 2017 Jul 11;8(28):45687-45697. doi: 10.18632/oncotarget.17669. Oncotarget. 2017. PMID: 28537899 Free PMC article.
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3. Nature. 2010. PMID: 20130576
-
Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.Cells. 2022 Feb 9;11(4):593. doi: 10.3390/cells11040593. Cells. 2022. PMID: 35203244 Free PMC article. Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
Cited by
-
Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.J Hematop. 2023 Dec;16(4):227-234. doi: 10.1007/s12308-023-00567-2. Epub 2023 Nov 23. J Hematop. 2023. PMID: 38175436
-
The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.J Invest Dermatol. 2022 Dec;142(12):3253-3261.e4. doi: 10.1016/j.jid.2022.06.005. Epub 2022 Jul 1. J Invest Dermatol. 2022. PMID: 35787399 Free PMC article.
-
Cutaneous T-cell lymphoma in SHOC2 mutation-associated Noonan-like syndrome with loose anagen hair.JAAD Case Rep. 2022 Apr 26;24:52-55. doi: 10.1016/j.jdcr.2022.04.009. eCollection 2022 Jun. JAAD Case Rep. 2022. PMID: 35600568 Free PMC article. No abstract available.
-
Targeted Deep Sequencing of Mycosis Fungoides Reveals Intracellular Signaling Pathways Associated with Aggressiveness and Large Cell Transformation.Cancers (Basel). 2021 Nov 2;13(21):5512. doi: 10.3390/cancers13215512. Cancers (Basel). 2021. PMID: 34771672 Free PMC article.
-
Cutaneous T cell lymphoma.Nat Rev Dis Primers. 2021 Aug 26;7(1):61. doi: 10.1038/s41572-021-00296-9. Nat Rev Dis Primers. 2021. PMID: 34446710 Review.
References
-
- van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood. 2009;113(1):127–136. - PubMed
-
- Caprini E, Cristofoletti C, Arcelli D, et al. Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. Cancer Res. 2009;69(21):8438–8446. - PubMed
-
- Carbone A, Bernardini L, Valenzano F, et al. Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF. Genes Chromosomes Cancer. 2008;47(12):1067–1075. - PubMed
-
- Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res. 2008;68(8):2689–2698. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous